Notably, Dexcom continues to innovate, with a future iteration of its CGM on the way. Sayer described the next-generation ...

Abbott (NYSE:ABT) today highlighted significant growth within its Diabetes business amid its fourth-quarter results for 2024.

Beta Bionics today filed a prospectus outlining its aim to bring in $114.4 million in its initial public offering (IPO).